Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice
Avacopan has been found to demonstrate both safety and high efficacy in the treatment of AAV in real-world settings, with remission rates exceeding and serious infection rates comparable to those observed in clinical trial data. However, the higher incidence of hepatotoxicity in certain populations underscores the need for careful monitoring and pharmacovigilance studies to clarify risk factors and guide patient selection.
Authors
- Andreas Kronbichler (ORCID: https://orcid.org/0000-0002-2945-2946)
- Felix Keller (ORCID: https://orcid.org/0000-0002-8240-7255)
- Peong Gang Park (ORCID: https://orcid.org/0000-0002-4389-7917)
- Jae Il Shin (ORCID: https://orcid.org/0000-0003-2326-1820)
- Clemens Untersulzner (ORCID: https://orcid.org/0009-0001-1768-7414)
- Sarah Soyeon Oh
- Ilay Berke
- Jasper Callemeyn
Institutions
- Linköping University (SE)
- Innsbruck Medical University (AT)
- Yonsei University (KR)
- Empowerment Program (US)
- KU Leuven (BE)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1016/j.ekir.2025.103753
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- AstraZeneca
- Argenx
- Yonsei University
- Novo Nordisk
- Swedish Orphan Biovitrum